CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Sadeleştirilmiş öğe sayfası
dc.contributor.authorSchnell, Oliver
dc.contributor.authorBarnard\\-Kelly, Katharine
dc.contributor.authorBattelino, Tadej
dc.contributor.authorCeriello, Antonio
dc.contributor.authorLarsson, Helena Elding
dc.contributor.authorFernandez\\-Fernandez, Beatriz
dc.contributor.authorForst, Thomas
dc.contributor.authorFrias, Juan \\-Pablo
dc.contributor.authorGavin III, James R.
dc.contributor.authorGiorgino, Francesco
dc.contributor.authorGroop, Per \\-Henrik
dc.contributor.authorHeerspink, Hiddo J. L.
dc.contributor.authorHerzig, Stephan
dc.contributor.authorHummel, Michael
dc.contributor.authorHuntley, George
dc.contributor.authorIbrahim, Mahmoud
dc.contributor.authorItzhak, Baruch
dc.contributor.authorJacob, Stephan
dc.contributor.authorJi, Linong
dc.contributor.authorKosiborod, Mikhail
dc.contributor.authorLalic, Nebosja
dc.contributor.authorMacieira, Sofia
dc.contributor.authorMalik, Rayaz A.
dc.contributor.authorMankovsky, Boris
dc.contributor.authorMarx, Nikolaus
dc.contributor.authorMathieu, Chantal
dc.contributor.authorMueller, Timo D.
dc.contributor.authorRay, Kausik
dc.contributor.authorRodbard, Helena W.
dc.contributor.authorRossing, Peter
dc.contributor.authorRyden, Lars
dc.contributor.authorSchumm\\-Draeger, Petra \\-Maria
dc.contributor.authorSchwarz, Peter
dc.contributor.authorSkrha, Jan
dc.contributor.authorSnoek, Frank
dc.contributor.authorTacke, Frank
dc.contributor.authorTaylor, Bruce
dc.contributor.authorJeppesen, Britta Tendal
dc.contributor.authorTesfaye, Solomon
dc.contributor.authorTopsever, Pinar
dc.contributor.authorVilsboll, Tina
dc.contributor.authorYu, Xuefeng
dc.contributor.authorStandl, Eberhard
dc.date.accessioned2025-10-16T15:15:19Z
dc.date.issued2023
dc.identifier.otherWOS:001243639800005
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6414
dc.publisherVERLAG KIRCHHEIM
dc.sourceDIABETES STOFFWECHSEL UND HERZ
dc.subjectCardiovascular disease Chronic kidney disease CGM Diabetes Finerenone
dc.subjectGLP\\-1 RA Guidelines Heart failure MASLD NAFLD Obesity SGLT2 inhibitor
dc.subjectTeplizumab
dc.titleCVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS